BioMed Research International / 2015 / Article / Tab 3

Research Article

Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study

Table 3

Chemotherapy regimens received after molecular profiling.

TreatmentNumberFrequency %

Combination therapy
FOLFIRI/XELIRI1634.0
GEMOX36.4
FOLFOX/XELOX 24.3
FOLFIRI + cetuximab24.3
Capecitabine + cisplatin12.1
5-FU + mitomycin12.1
5-FU + adriamycin + methotrexate12.1
Gemcitabine + nab-paclitaxel12.1
Gemcitabine + paclitaxel12.1
Oxaliplatin + bevacizumab12.1
Pegylated liposomal doxorubicin + cetuximab12.1

Monotherapy
5-FU/capecitabine510.6
Nab-paclitaxel 510.6
Sunitinib12.1
Cetuximab12.1
Gemcitabine 12.1
Sorafenib12.1
Temozolomide12.1
Mitomycin12.1
Everolimus 12.1

Total of regimens received 47100

5-FU: 5-fluorouracil; FOLFIRI: 5-fluorouracil/irinotecan; FOLFOX: 5-fluorouracil/oxaliplatin; GEMOX: gemcitabine/oxaliplatin; XELIRI: capecitabine/irinotecan; XELOX: capecitabine/oxaliplatin.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.